Ultragenyx CMO helms rare disease team
Dr. Camille Bedrosian has spent much of her career in the biotech sector, primarily working with rare diseases.
“It’s a different level of commitment and tenacity, not taking no for an answer to solve a problem,” she said. “It’s been a little over two decades for me, and I’ve always been in rare disease.”
Bedrosian previously helped to build a development group at Alexion Pharmaceuticals Inc. working on small molecules for oncology, focusing on rare cancers such as sarcoma.
Camille…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Nathan Falstreau Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Pharmaceuticals | Rare Diseases | Sarcomas